Feb 12 (Reuters) - Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems. The company ...
Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...
Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.
Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
Zacks Investment Research on MSN
Dexcom stock falls despite Q4 earnings beat, G7 rollout drives growth
DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...
DexCom reported worldwide revenue of $1.26 billion versus $1.11 billion a year earlier, marking 13% reported growth and 12% organic. U.S. Q4 revenue climbed 11% year over year to $892 million, while ...
Investing.com - DexCom (NASDAQ: DXCM) reported fourth quarter EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $1.26B versus the consensus estimate of ...
DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results